Ranitidine
 Ranitidine  injection
 Ranitidine Tablets

Drugspedia.net

|Ranitidine Ranitidine injection Ranitidine Tablets

Drugs search, click the first letter of a drug name: | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9

   


Ranitidine


Generic Name: Ranitidine
Dosage Form: Tablets usp

Ranitidine Description

Ranitidine hydrochloride (HCl) is a histamine H2-receptor antagonist. Chemically it is N-[ 2-[[[5-[(Dimethylamino)methyl]-2-furanyl] methyl]thio]ethyl]-N"-methyl-2-nitro-1,1-ethenediamine, HCl. It has the following structure:

The empirical formula is C13H22N4O3S·HCl, representing a molecular weight of 350.87.

Ranitidine HCl is a white to pale yellow, granular substance that is soluble in water. It has a slightly bitter taste and sulfur-like odor.

Each tablet, for oral administration, contains 168 mg of Ranitidine HCl equivalent to 150 mg of Ranitidine, or 336 mg of Ranitidine HCl equivalent to 300 mg of Ranitidine. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, maltodextrin, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium bicarbonate, synthetic red iron oxide, synthetic yellow iron oxide, talc, titanium dioxide and triethyl citrate.

Ranitidine - Clinical Pharmacology

Ranitidine is a competitive, reversible inhibitor of the action of histamine at the histamine H2-receptors, including receptors on the gastric cells. Ranitidine does not lower serum Ca++ in hypercalcemic states. Ranitidine is not an anticholinergic agent.

Pharmacokinetics

Absorption

Ranitidine is 50% absorbed after oral administration, compared to an intravenous (IV) injection with mean peak levels of 440 to 545 ng/mL occurring at 2 to 3 hours after a 150 mg dose. Absorption is not significantly impaired by the administration of food or antacids. Propantheline slightly delays and increases peak blood levels of Ranitidine, probably by delaying gastric emptying and transit time. In one study, simultaneous administration of high-potency antacid (150 mmol) in fasting subjects has been reported to decrease the absorption of Ranitidine.

Distribution

The volume of distribution is about 1.4 L/kg. Serum protein binding averages 15%.

Metabolism

In humans, the N-oxide is the principal metabolite in the urine; however, this amounts to <4% of the dose. Other metabolites are the S-oxide (1%) and the desmethyl Ranitidine (1%). The remainder of the administered dose is found in the stool. Studies in patients with hepatic dysfunction (compensated cirrhosis) indicate that there are minor, but clinically insignificant, alterations in Ranitidine half-life, distribution, clearance, and bioavailability.

Excretion

The principal route of excretion is the urine, with approximately 30% of the orally administered dose collected in the urine as unchanged drug in 24 hours. Renal clearance is about 410 mL/min, indicating active tubular excretion. The elimination half-life is 2.5 to 3 hours. Four patients with clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min) administered 50 mg of Ranitidine intravenously had an average plasma half-life of 4.8 hours, a Ranitidine clearance of 29 mL/min, and a volume of distribution of 1.76 L/kg. In general, these parameters appear to be altered in proportion to creatinine clearance (see DOSAGE AND ADMINISTRATION).

Geriatrics

The plasma half-life is prolonged and total clearance is reduced in the elderly population due to a decrease in renal function. The elimination half-life is 3 to 4 hours. Peak levels average 526 ng/mL following a 150 mg twice daily dose and occur in about 3 hours (see PRECAUTIONS: Geriatric Use and DOSAGE AND ADMINISTRATION: Dosage Adjustment for Patients with Impaired Renal Function).

Pediatrics

There are no significant differences in the pharmacological parameter values for Ranitidine in pediatric patients (from 1 month up to 16 years of age) and healthy adults when correction is made for body weight. The average bioavailability of Ranitidine given orally to pediatric patients is 48% which is comparable to the bioavailability of Ranitidine in the adult population. All other pharmacokinetic parameter values (t1/2, Vd, and CL) are similar to those observed with intravenous Ranitidine use in pediatric patients. Estimates of Cmax and Tmax are displayed in Table 1.

Table 1. Ranitidine Pharmacokinetics in Pediatric Patients Following Oral Dosing
Population Dosage Form Cmax Tmax
(age) n (dose) (ng/mL) (hours)
Gastric or duodenal ulcer Tablets 54 to 492 2.0
(3.5 to 16 years) 12 (1 to 2 mg/kg)
Otherwise healthy requiring Ranitidine Syrup 244 1.61
(0.7 to 14 years, Single dose) 10 (2 mg/kg)
Otherwise healthy requiring Ranitidine Syrup 320 1.66
(0.7 to 14 years, Multiple dose) 10 (2 mg/kg)

Plasma clearance measured in 2 neonatal patients (less than 1 month of age) was considerably lower (3 mL/min/kg) than children or adults and is likely due to reduced renal function observed in this population (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION: Pediatric Use).

Pharmacodynamics

Serum concentrations necessary to inhibit 50% of stimulated gastric acid secretion are estimated to be 36 to 94 ng/mL. Following a single oral dose of 150 mg, serum concentrations of Ranitidine are in this range up to 12 hours. However, blood levels bear no consistent relationship to dose or degree of acid inhibition.

Antisecretory Activity

1. Effects on Acid Secretion: Ranitidine inhibits both daytime and nocturnal basal gastric acid secretions as well as gastric acid secretion stimulated by food, betazole, and pentagastrin, as shown in Table 2:

Table 2: Effect of Oral Ranitidine on Gastric Acid Secretion
Time After Dose, % Inhibition of Gastric Acid Output
h by Dose, mg
75-80 100 150 200
Basal Up to 4 99 95
Nocturnal Up to 13 95 96 92
Betazole Up to 3 97 99
Pentagastrin Up to 5 58 72 72 80
Meal Up to 3 73 79 95

It appears that basal-, nocturnal-, and betazole-stimulated secretions are most sensitive to inhibition by Ranitidine, responding almost completely to doses of 100 mg or less, while pentagastrin- and food-stimulated secretions are more difficult to suppress.

2. Effects on Other Gastrointestinal Secretions:

Pepsin: Oral Ranitidine does not affect pepsin secretion. Total pepsin output is reduced in proportion to the decrease in volume of gastric juice.

Intrinsic Factor: Oral Ranitidine has no significant effect on pentagastrin-stimulated intrinsic factor secretion.

Serum Gastrin: Ranitidine has little or no effect on fasting or postprandial serum gastrin.

Other Pharmacologic Actions:

  1. Gastric bacterial flora–increase in nitrate-reducing organisms, significance not known.

  2. Prolactin levels–no effect in recommended oral or intravenous (IV) dosage, but small, transient, dose-related increases in serum prolactin have been reported after IV bolus injections of 100 mg or more.

  3. Other pituitary hormones–no effect on serum gonadotropins, TSH, or GH. Possible impairment of vasopressin release.

  4. No change in cortisol, aldosterone, androgen, or estrogen levels.

  5. No antiandrogenic action.

  6. No effect on count, motility, or morphology of sperm.

Pediatrics: Oral doses of 6 to 10 mg/kg per day in 2 or 3 divided doses maintain gastric pH>4 throughout most of the dosing interval.

Clinical Trials

Active Duodenal Ulcer

In a multicenter, double-blind, controlled, US study of endoscopically diagnosed duodenal ulcers, earlier healing was seen in the patients treated with Ranitidine as shown in Table 3:

Table 3: Duodenal Ulcer Patient Healing Rates
Ranitidine* Placebo*
Number Healed/ Number Healed/
Entered Evaluable Entered Evaluable
*All patients were permitted p.r.n. antacids for relief of pain.
†P <0.0001
Outpatients
Week 2 69/182 31/164
(38%) (19%)
195 188
Week 4 137/187 76/168
(73%) (45%)

In these studies patients treated with Ranitidine reported a reduction in both daytime and nocturnal pain, and they also consumed less antacid than the placebo-treated patients.

Table 4: Mean Daily Doses of Antacid
Ulcer Healed Ulcer Not Healed
Ranitidine 0.06 0.71
Placebo 0.71 1.43

Foreign studies have shown that patients heal equally well with 150 mg b.i.d. and 300 mg h.s. (85% versus 84%, respectively) during a usual 4-week course of therapy. If patients require extended therapy of 8 weeks, the healing rate may be higher for 150 mg b.i.d. as compared to 300 mg h.s. (92% versus 87%, respectively). Studies have been limited to short-term treatment of acute duodenal ulcer. Patients whose ulcers healed during therapy had recurrences of ulcers at the usual rates.

Maintenance Therapy in Duodenal Ulcer

Ranitidine has been found to be effective as maintenance therapy for patients following healing of acute duodenal ulcers. In 2 independent, double-blind, multicenter, controlled trials, the number of duodenal ulcers observed was significantly less in patients treated with Ranitidine (150 mg h.s.) than in patients treated with placebo over a 12-month period.

Table 5: Duodenal Ulcer Prevalence
Double-blind, Multicenter, Placebo-Controlled Trials
Multicenter Number of
Trial Drug Duodenal Ulcer Prevalence Patients
0-4 0-8 0-12
Months Months Months
%=Life table estimate
*=P <0.05 (Ranitidine versus comparator).
RAN=Ranitidine
PLC=placebo
USA RAN 20%* 24%* 35%* 138
PLC 44% 54% 59% 139
RAN 12%* 21%* 28%* 174
Foreign PLC 56% 64% 68% 165

As with other H2-antagonists, the factors responsible for the significant reduction in the prevalence of duodenal ulcers include prevention of recurrence of ulcers, more rapid healing of ulcers that may occur during maintenance therapy, or both.

Gastric Ulcer

In a multicenter, double-blind, controlled, US study of endoscopically diagnosed gastric ulcers, earlier healing was seen in the patients treated with Ranitidine as shown in Table 6:

Table 6: Gastric Ulcer Patient Healing Rates
Ranitidine* Placebo*
Number Healed/ Number Healed/
Entered Evaluable Entered Evaluable
*All patients were permitted p.r.n. antacids for relief of pain.
†P =0.0009
Outpatients
Week 2 16/83 10/83
(19%) (12%)
92 94
Week 6 50/73 35/69
(68%) (51%)

In this multicenter trial, significantly more patients treated with Ranitidine became pain-free during therapy.

Maintenance of Healing of Gastric Ulcers

In 2 multicenter, double-blind, randomized, placebo-controlled, 12-month trials conducted in patients whose gastric ulcers had been previously healed, Ranitidine 150 mg h.s. was significantly more effective than placebo in maintaining healing of gastric ulcers.

Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome)

Ranitidine inhibits gastric acid secretion and reduces occurrence of diarrhea, anorexia, and pain in patients with pathological hypersecretion associated with Zollinger-Ellison syndrome, systemic mastocytosis, and other pathological hypersecretory conditions (e.g., postoperative, “short-gut” syndrome, idiopathic). Use of Ranitidine was followed by healing of ulcers in 8 of 19 (42%) patients who were intractable to previous therapy.

Gastroesophageal Reflux Disease (GERD)

In 2 multicenter, double-blind, placebo-controlled, 6-week trials performed in the United States and Europe, Ranitidine 150 mg b.i.d. was more effective than placebo for the relief of heartburn and other symptoms associated with GERD. Ranitidine-treated patients consumed significantly less antacid than did placebo-treated patients.

The US trial indicated that Ranitidine 150 mg b.i.d. significantly reduced the frequency of heartburn attacks and severity of heartburn pain within 1 to 2 weeks after starting therapy. The improvement was maintained throughout the 6-week trial period. Moreover, patient response rates demonstrated that the effect on heartburn extends through both the day and night time periods.

In 2 additional US multicenter, double-blind, placebo-controlled, 2-week trials, Ranitidine 150 mg b.i.d. was shown to provide relief of heartburn pain within 24 hours of initiating therapy and a reduction in the frequency and severity of heartburn.

Erosive Esophagitis

In 2 multicenter, double-blind, randomized, placebo-controlled, 12-week trials performed in the United States, Ranitidine 150 mg q.i.d. was significantly more effective than placebo in healing endoscopically diagnosed erosive esophagitis and in relieving associated heartburn. The erosive esophagitis healing rates were as follows:

Table 7: Erosive Esophagitis Patient Healing Rates
Healed/Evaluable
Ranitidine
Placebo* 150 mg q.i.d.*
n=229 n=215
*All patients were permitted p.r.n antacids for relief of pain.
†P <0.001 versus placebo.
Week 4 43/198 (22%) 96/206 (47%)
Week 8 63/176 (36%) 142/200 (71%)
Week 12 92/159 (58%) 162/192 (84%)

No additional benefit in healing of esophagitis or in relief of heartburn was seen with a Ranitidine dose of 300 mg q.i.d.

Maintenance of Healing of Erosive Esophagitis

In 2 multicenter, double-blind, randomized, placebo-controlled, 48-week trials conducted in patients whose erosive esophagitis had been previously healed, Ranitidine 150 mg b.i.d. was significantly more effective than placebo in maintaining healing of erosive esophagitis.

Indications and Usage for Ranitidine

Ranitidine tablets are indicated in:

  1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of Ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks.

  2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year.

  3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis).

  4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of Ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks.

  5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year.

  6. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine 150 mg b.i.d.

  7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine 150 mg q.i.d.

  8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks.

Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.

Contraindications

Ranitidine is contraindicated for patients known to have hypersensitivity to the drug or any of the ingredients (see PRECAUTIONS).

Precautions

General

  1. Symptomatic response to Ranitidine therapy does not preclude the presence of gastric malignancy.

  2. Since Ranitidine is excreted primarily by the kidney, dosage should be adjusted in patients with impaired renal function (see DOSAGE AND ADMINISTRATION). Caution should be observed in patients with hepatic dysfunction since Ranitidine is metabolized in the liver.

  3. Rare reports suggest that Ranitidine may precipitate acute porphyric attacks in patients with acute porphyria. Ranitidine should therefore be avoided in patients with a history of acute porphyria.

Laboratory Tests

False-positive tests for urine protein with Multistix® may occur during Ranitidine therapy, and therefore testing with sulfosalicylic acid is recommended.

Drug Interactions

Although Ranitidine has been reported to bind weakly to cytochrome P-450 in vitro, recommended doses of the drug do not inhibit the action of the cytochrome P-450-linked oxygenase enzymes in the liver. However, there have been isolated reports of drug interactions that suggest that Ranitidine may affect the bioavailability of certain drugs by some mechanism as yet unidentified (e.g., a pH-dependent effect on absorption or a change in volume of distribution).

Increased or decreased prothrombin times have been reported during concurrent use of Ranitidine and warfarin. However, in human pharmacokinetic studies with dosages of Ranitidine up to 400 mg per day, no interaction occurred; Ranitidine had no effect on warfarin clearance or prothrombin time. The possibility of an interaction with warfarin at dosages of Ranitidine higher than 400 mg per day has not been investigated.

In a Ranitidine-triazolam drug-drug interaction study, triazolam plasma concentrations were higher during b.i.d. dosing of Ranitidine than triazolam given alone. The mean area under the triazolam concentration-time curve (AUC) values in 18- to 60-year-old subjects were 10% and 28% higher following administration of 75 mg and 150 mg Ranitidine tablets, respectively, than triazolam given alone. In subjects older than 60 years of age, the mean AUC values were approximately 30% higher following administration of 75 mg and 150 mg Ranitidine tablets. It appears that there were no changes in pharmacokinetics of triazolam and α-hydroxytriazolam, a major metabolite, and in their elimination. Reduced gastric acidity due to Ranitidine may have resulted in an increase in the availability of triazolam. The clinical significance of this triazolam and Ranitidine pharmacokinetic interaction is unknown.

Carcinogenesis, Mutagenesis, Impairment of Fertility

There was no indication of tumorigenic or carcinogenic effects in life-span studies in mice and rats at dosages up to 2,000 mg/kg per day.

Ranitidine was not mutagenic in standard bacterial tests (Salmonella, Escherichia coli ) for mutagenicity at concentrations up to the maximum recommended for these assays.

In a dominant lethal assay, a single oral dose of 1,000 mg/kg to male rats was without effect on the outcome of 2 matings per week for the next 9 weeks.

Pregnancy

Teratogenic Effects

Pregnancy Category B: Reproduction studies have been performed in rats and rabbits at doses up to 160 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Ranitidine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

Ranitidine is secreted in human milk. Caution should be exercised when Ranitidine is administered to a nursing mother.

Pediatric Use

The safety and effectiveness of Ranitidine has been established in the age-group of 1 month to 16 years for the treatment of duodenal and gastric ulcers, gastroesophageal reflux disease and erosive esophagitis, and the maintenance of healed duodenal and gastric ulcer. Use of Ranitidine in this age-group is supported by adequate and well-controlled studies in adults, as well as additional pharmacokinetic data in pediatric patients and an analysis of the published literature (See CLINICAL PHARMACOLOGY: Pediatrics and DOSAGE AND ADMINISTRATION: Pediatric Use).

Safety and effectiveness in pediatric patients for the treatment of pathological hypersecretory conditions or the maintenance of healing of erosive esophagitis have not been established.

Safety and effectiveness in neonates (less than 1 month of age) have not been established (see CLINICAL PHARMACOLOGY: Pediatrics).

Geriatric Use

Of the total number of subjects enrolled in US and foreign controlled clinical trials of oral formulations of Ranitidine, for which there were subgroups analyses, 4197 were 65 and over, while 899 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, caution should be exercised in dose selection, and it may be useful to monitor renal function (see CLINICAL PHARMACOLOGY: Pharmacokinetics: Geriatrics and DOSAGE AND ADMINISTRATION: Dosage Adjustment for Patients with Impaired Renal Function).

Adverse Reactions

The following have been reported as events in clinical trials or in the routine management of patients treated with Ranitidine. The relationship to Ranitidine therapy has been unclear in many cases. Headache, sometimes severe, seems to be related to administration of Ranitidine.

Central Nervous System: Rarely, malaise, dizziness, somnolence, insomnia, and vertigo. Rare cases of reversible mental confusion, agitation, depression, and hallucinations have been reported, predominantly in severely ill elderly patients. Rare cases of reversible blurred vision suggestive of a change in accommodation have been reported. Rare reports of reversible involuntary motor disturbances have been received.

Cardiovascular: As with other H2-blockers, rare reports of arrhythmias such as tachycardia, bradycardia, atrioventricular block, and premature ventricular beats.

Gastrointestinal: Constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain, and rare reports of pancreatitis.

Hepatic: There have been occasional reports of hepatocellular, cholestatic, or mixed hepatitis, with or without jaundice. In such circumstances, Ranitidine should be immediately discontinued. These events are usually reversible, but in rare circumstances death has occurred. Rare cases of hepatic failure have also been reported. In normal volunteers, SGPT values were increased to at least twice the pretreatment levels in 6 of 12 subjects receiving 100 mg q.i.d. intravenously for 7 days, and in 4 of 24 subjects receiving 50 mg q.i.d. intravenously for 5 days.

Musculoskeletal: Rare reports of arthralgias and myalgias.

Hematologic: Blood count changes (leukopenia, granulocytopenia, and thrombocytopenia) have occurred in a few patients. These were usually reversible. Rare cases of agranulocytosis, pancytopenia, sometimes with marrow hypoplasia, and aplastic anemia and exceedingly rare cases of acquired immune hemolytic anemia have been reported.

Endocrine: Controlled studies in animals and man have shown no stimulation of any pituitary hormone by Ranitidine and no antiandrogenic activity, and cimetidine-induced gynecomastia and impotence in hypersecretory patients have resolved when Ranitidine has been substituted. However, occasional cases of gynecomastia, impotence, and loss of libido have been reported in male patients receiving Ranitidine, but the incidence did not differ from that in the general population.

Integumentary: Rash, including rare cases of erythema multiforme. Rare cases of alopecia and vasculitis.

Other: Rare cases of hypersensitivity reactions (e.g., bronchospasm, fever, rash, eosinophilia), anaphylaxis, angioneurotic edema, and small increases in serum creatinine.

Overdosage

There has been limited experience with overdosage. Reported acute ingestions of up to 18 g orally have been associated with transient adverse effects similar to those encountered in normal clinical experience (see ADVERSE REACTIONS). In addition, abnormalities of gait and hypotension have been reported.

When overdosage occurs, the usual measures to remove unabsorbed material from the gastrointestinal tract, clinical monitoring, and supportive therapy should be employed.

Studies in dogs receiving dosages of Ranitidine in excess of 225 mg/kg per day have shown muscular tremors, vomiting, and rapid respiration. Single oral doses of 1,000 mg/kg in mice and rats were not lethal. Intravenous LD50 values in mice and rats were 77 and 83 mg/kg, respectively.

Ranitidine Dosage and Administration

Active Duodenal Ulcer

The current recommended adult oral dosage of Ranitidine for duodenal ulcer is 150 mg twice daily. An alternative dosage of 300 mg once daily after the evening meal or at bedtime can be used for patients in whom dosing convenience is important. The advantages of one treatment regimen compared to the other in a particular patient population have yet to be demonstrated (see CLINICAL PHARMACOLOGY, Clinical Trials: Active Duodenal Ulcer). Smaller doses have been shown to be equally effective in inhibiting gastric acid secretion in US studies, and several foreign trials have shown that 100 mg twice daily is as effective as the 150 mg dose. Antacid should be given as needed for relief of pain (see CLINICAL PHARMACOLOGY: Pharmacokinetics).

Maintenance of Healing of Duodenal Ulcers

The current recommended adult oral dosage is 150 mg at bedtime.

Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome)

The current recommended adult oral dosage is 150 mg twice a day. In some patients it may be necessary to administer Ranitidine 150 mg dosages more frequently. Dosages should be adjusted to individual patient needs, and should continue as long as clinically indicated. Dosages up to 6 g/day have been employed in patients with severe disease.

Benign Gastric Ulcer

The current recommended adult oral dosage is 150 mg twice a day.

Maintenance of Healing of Gastric Ulcers

The current recommended adult oral dosage is 150 mg at bedtime.

GERD

The current recommended adult oral dosage is 150 mg twice a day.

Erosive Esophagitis

The current recommended adult oral dosage is 150 mg 4 times a day.

Maintenance of Healing of Erosive Esophagitis

The current recommended adult oral dosage is 150 mg twice a day.

Pediatric Use

The safety and effectiveness of Ranitidine has been established in the age-group of 1 month to 16 years. There is insufficient information about the pharmacokinetics of Ranitidine in neonatal patients (less than 1 month of age) to make dosing recommendations.

The following 3 subsections provide dosing information for each of the pediatric indications.

Treatment of Duodenal and Gastric Ulcers

The recommended oral dose for the treatment of active duodenal and gastric ulcers is 2 to 4 mg/kg twice daily to a maximum of 300 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients.

Maintenance of Healing of Duodenal and Gastric Ulcers

The recommended oral dose for the maintenance of healing of duodenal and gastric ulcers is 2 to 4 mg/kg once daily to a maximum of 150 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients.

Treatment of GERD and Erosive Esophagitis

Although limited data exist for these conditions in pediatric patients, published literature supports a dosage of 5 to 10 mg/kg per day, usually given as 2 divided doses.

Dosage Adjustment for Patients with Impaired Renal Function

On the basis of experience with a group of subjects with severely impaired renal function treated with Ranitidine, the recommended dosage in patients with a creatinine clearance < 50 mL/min is 150 mg every 24 hours. Should the patient’s condition require, the frequency of dosing may be increased to every 12 hours or even further with caution. Hemodialysis reduces the level of circulating Ranitidine. Ideally, the dosing schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.

Elderly patients are more likely to have decreased renal function, therefore caution should be exercised in dose selection, and it may be useful to monitor renal function (see CLINICAL PHARMACOLOGY: Pharmacokinetics: Geriatrics and PRECAUTIONS: Geriatric Use).

HOW SUPPLIED:

Ranitidine Tablets USP (each tablet contains Ranitidine hydrochloride equivalent to either 150 mg or 300 mg Ranitidine) are supplied as follows:

150 mg: Beige, round, biconvex tablet debossed WATSON in a semi-circle around the top edge and 760 across the bottom of one side and plain on the other side, in bottles of 60 and 500.

300 mg: Beige, capsule-shaped, biconvex, film-coated tablet debossed WATSON in a semi-circle around the top edge and 761 across the bottom of one side and plain on the other, in bottles of 30 and 100.

Store at 20°-25°C (68°-77°F) in a dry place. [See USP controlled room temperature.] Protect from light. Replace cap securely after each opening.

Dispense in a tight, light-resistant container as defined in USP/NF.

Manufactured for:
Watson Laboratories, Inc.
Corona, CA 92880 USA

Manufactured by:
Patheon Pharmaceuticals Inc.
Cincinnati, OH 45237 USA
Rev: June 2005


Ranitidine Hydrochloride (Ranitidine Hydrochloride)
PRODUCT INFO
Product Code 0591-0760 Dosage Form TABLET
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Ranitidine Hydrochloride (Ranitidine) Active 150 MILLIGRAM  In 1 TABLET
Colloidal silicon dioxide Inactive  
Hypromellose Inactive  
Magnesium stearate Inactive  
Maltodextrin Inactive  
Microcrystalline cellulose Inactive  
Polydextrose Inactive  
Polyethylene glycol Inactive  
Sodium bicarbonate Inactive  
Synthetic red iron oxide Inactive  
Synthetic yellow iron oxide Inactive  
Talc Inactive  
Titanium dioxide Inactive  
Triethyl citrate Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color GRAY (Beige) Score 1
Shape ROUND (Round) Symbol false
Imprint Code WATSON;760 Coating false
Size 16mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0591-0760-60 60 TABLET In 1 BOTTLE None
2 0591-0760-05 500 TABLET In 1 BOTTLE None

Ranitidine Hydrochloride (Ranitidine Hydrochloride)
PRODUCT INFO
Product Code 0591-0761 Dosage Form TABLET
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Ranitidine Hydrochloride (Ranitidine) Active 300 MILLIGRAM  In 1 TABLET
Colloidal silicon dioxide Inactive  
Hypromellose Inactive  
Magnesium stearate Inactive  
Maltodextrin Inactive  
Microcrystalline cellulose Inactive  
Polydextrose Inactive  
Polyethylene glycol Inactive  
Sodium bicarbonate Inactive  
Synthetic red iron oxide Inactive  
Synthetic yellow iron oxide Inactive  
Talc Inactive  
Titanium dioxide Inactive  
Triethyl citrate Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color GRAY (Beige) Score 1
Shape OVAL (Capsule-shaped) Symbol false
Imprint Code WATSON;761 Coating true
Size 16mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0591-0761-30 30 TABLET In 1 BOTTLE None
2 0591-0761-01 100 TABLET In 1 BOTTLE None

Revised: 12/2006





1

eanitidine ranitidine injection ranitidine tablets, danitidine ranitidine injection ranitidine tablets, fanitidine ranitidine injection ranitidine tablets, tanitidine ranitidine injection ranitidine tablets, 5anitidine ranitidine injection ranitidine tablets, 4anitidine ranitidine injection ranitidine tablets, rznitidine ranitidine injection ranitidine tablets, rsnitidine ranitidine injection ranitidine tablets, rwnitidine ranitidine injection ranitidine tablets, rqnitidine ranitidine injection ranitidine tablets, rabitidine ranitidine injection ranitidine tablets, ramitidine ranitidine injection ranitidine tablets, rajitidine ranitidine injection ranitidine tablets, rahitidine ranitidine injection ranitidine tablets, ranutidine ranitidine injection ranitidine tablets, ranjtidine ranitidine injection ranitidine tablets, ranktidine ranitidine injection ranitidine tablets, ranotidine ranitidine injection ranitidine tablets, ran9tidine ranitidine injection ranitidine tablets, ran8tidine ranitidine injection ranitidine tablets, raniridine ranitidine injection ranitidine tablets, ranifidine ranitidine injection ranitidine tablets, ranigidine ranitidine injection ranitidine tablets, raniyidine ranitidine injection ranitidine tablets, rani6idine ranitidine injection ranitidine tablets, rani5idine ranitidine injection ranitidine tablets, ranitudine ranitidine injection ranitidine tablets, ranitjdine ranitidine injection ranitidine tablets, ranitkdine ranitidine injection ranitidine tablets, ranitodine ranitidine injection ranitidine tablets, ranit9dine ranitidine injection ranitidine tablets, ranit8dine ranitidine injection ranitidine tablets, ranitisine ranitidine injection ranitidine tablets, ranitixine ranitidine injection ranitidine tablets, raniticine ranitidine injection ranitidine tablets, ranitifine ranitidine injection ranitidine tablets, ranitirine ranitidine injection ranitidine tablets, ranitieine ranitidine injection ranitidine tablets, ranitidune ranitidine injection ranitidine tablets, ranitidjne ranitidine injection ranitidine tablets, ranitidkne ranitidine injection ranitidine tablets, ranitidone ranitidine injection ranitidine tablets, ranitid9ne ranitidine injection ranitidine tablets, ranitid8ne ranitidine injection ranitidine tablets, ranitidibe ranitidine injection ranitidine tablets, ranitidime ranitidine injection ranitidine tablets, ranitidije ranitidine injection ranitidine tablets, ranitidihe ranitidine injection ranitidine tablets, ranitidinw ranitidine injection ranitidine tablets, ranitidins ranitidine injection ranitidine tablets, ranitidind ranitidine injection ranitidine tablets, ranitidinr ranitidine injection ranitidine tablets, ranitidin4 ranitidine injection ranitidine tablets, ranitidin3 ranitidine injection ranitidine tablets, ranitidine eanitidine injection ranitidine tablets, ranitidine danitidine injection ranitidine tablets, ranitidine fanitidine injection ranitidine tablets, ranitidine tanitidine injection ranitidine tablets, ranitidine 5anitidine injection ranitidine tablets, ranitidine 4anitidine injection ranitidine tablets, ranitidine rznitidine injection ranitidine tablets, ranitidine rsnitidine injection ranitidine tablets, ranitidine rwnitidine injection ranitidine tablets, ranitidine rqnitidine injection ranitidine tablets, ranitidine rabitidine injection ranitidine tablets, ranitidine ramitidine injection ranitidine tablets, ranitidine rajitidine injection ranitidine tablets, ranitidine rahitidine injection ranitidine tablets, ranitidine ranutidine injection ranitidine tablets, ranitidine ranjtidine injection ranitidine tablets, ranitidine ranktidine injection ranitidine tablets, ranitidine ranotidine injection ranitidine tablets, ranitidine ran9tidine injection ranitidine tablets, ranitidine ran8tidine injection ranitidine tablets, ranitidine raniridine injection ranitidine tablets, ranitidine ranifidine injection ranitidine tablets, ranitidine ranigidine injection ranitidine tablets, ranitidine raniyidine injection ranitidine tablets, ranitidine rani6idine injection ranitidine tablets, ranitidine rani5idine injection ranitidine tablets, ranitidine ranitudine injection ranitidine tablets, ranitidine ranitjdine injection ranitidine tablets, ranitidine ranitkdine injection ranitidine tablets, ranitidine ranitodine injection ranitidine tablets, ranitidine ranit9dine injection ranitidine tablets, ranitidine ranit8dine injection ranitidine tablets, ranitidine ranitisine injection ranitidine tablets, ranitidine ranitixine injection ranitidine tablets, ranitidine raniticine injection ranitidine tablets, ranitidine ranitifine injection ranitidine tablets, ranitidine ranitirine injection ranitidine tablets, ranitidine ranitieine injection ranitidine tablets, ranitidine ranitidune injection ranitidine tablets, ranitidine ranitidjne injection ranitidine tablets, ranitidine ranitidkne injection ranitidine tablets, ranitidine ranitidone injection ranitidine tablets, ranitidine ranitid9ne injection ranitidine tablets, ranitidine ranitid8ne injection ranitidine tablets, ranitidine ranitidibe injection ranitidine tablets, ranitidine ranitidime injection ranitidine tablets, ranitidine ranitidije injection ranitidine tablets, ranitidine ranitidihe injection ranitidine tablets, ranitidine ranitidinw injection ranitidine tablets, ranitidine ranitidins injection ranitidine tablets, ranitidine ranitidind injection ranitidine tablets, ranitidine ranitidinr injection ranitidine tablets, ranitidine ranitidin4 injection ranitidine tablets, ranitidine ranitidin3 injection ranitidine tablets, ranitidine ranitidine unjection ranitidine tablets, ranitidine ranitidine jnjection ranitidine tablets, ranitidine ranitidine knjection ranitidine tablets, ranitidine ranitidine onjection ranitidine tablets, ranitidine ranitidine 9njection ranitidine tablets, ranitidine ranitidine 8njection ranitidine tablets, ranitidine ranitidine ibjection ranitidine tablets, ranitidine ranitidine imjection ranitidine tablets, ranitidine ranitidine ijjection ranitidine tablets, ranitidine ranitidine ihjection ranitidine tablets, ranitidine ranitidine inhection ranitidine tablets, ranitidine ranitidine innection ranitidine tablets, ranitidine ranitidine inmection ranitidine tablets, ranitidine ranitidine inkection ranitidine tablets, ranitidine ranitidine iniection ranitidine tablets, ranitidine ranitidine inuection ranitidine tablets, ranitidine ranitidine injwction ranitidine tablets, ranitidine ranitidine injsction ranitidine tablets, ranitidine ranitidine injdction ranitidine tablets, ranitidine ranitidine injrction ranitidine tablets, ranitidine ranitidine inj4ction ranitidine tablets, ranitidine ranitidine inj3ction ranitidine tablets, ranitidine ranitidine injextion ranitidine tablets, ranitidine ranitidine injevtion ranitidine tablets, ranitidine ranitidine injeftion ranitidine tablets, ranitidine ranitidine injedtion ranitidine tablets, ranitidine ranitidine injecrion ranitidine tablets, ranitidine ranitidine injecfion ranitidine tablets, ranitidine ranitidine injecgion ranitidine tablets, ranitidine ranitidine injecyion ranitidine tablets, ranitidine ranitidine injec6ion ranitidine tablets, ranitidine ranitidine injec5ion ranitidine tablets, ranitidine ranitidine injectuon ranitidine tablets, ranitidine ranitidine injectjon ranitidine tablets, ranitidine ranitidine injectkon ranitidine tablets, ranitidine ranitidine injectoon ranitidine tablets, ranitidine ranitidine inject9on ranitidine tablets, ranitidine ranitidine inject8on ranitidine tablets, ranitidine ranitidine injectiin ranitidine tablets, ranitidine ranitidine injectikn ranitidine tablets, ranitidine ranitidine injectiln ranitidine tablets, ranitidine ranitidine injectipn ranitidine tablets, ranitidine ranitidine injecti0n ranitidine tablets, ranitidine ranitidine injecti9n ranitidine tablets, ranitidine ranitidine injectiob ranitidine tablets, ranitidine ranitidine injectiom ranitidine tablets, ranitidine ranitidine injectioj ranitidine tablets, ranitidine ranitidine injectioh ranitidine tablets, ranitidine ranitidine injection eanitidine tablets, ranitidine ranitidine injection danitidine tablets, ranitidine ranitidine injection fanitidine tablets, ranitidine ranitidine injection tanitidine tablets, ranitidine ranitidine injection 5anitidine tablets, ranitidine ranitidine injection 4anitidine tablets, ranitidine ranitidine injection rznitidine tablets, ranitidine ranitidine injection rsnitidine tablets, ranitidine ranitidine injection rwnitidine tablets, ranitidine ranitidine injection rqnitidine tablets, ranitidine ranitidine injection rabitidine tablets, ranitidine ranitidine injection ramitidine tablets, ranitidine ranitidine injection rajitidine tablets, ranitidine ranitidine injection rahitidine tablets, ranitidine ranitidine injection ranutidine tablets, ranitidine ranitidine injection ranjtidine tablets, ranitidine ranitidine injection ranktidine tablets, ranitidine ranitidine injection ranotidine tablets, ranitidine ranitidine injection ran9tidine tablets, ranitidine ranitidine injection ran8tidine tablets, ranitidine ranitidine injection raniridine tablets, ranitidine ranitidine injection ranifidine tablets, ranitidine ranitidine injection ranigidine tablets, ranitidine ranitidine injection raniyidine tablets, ranitidine ranitidine injection rani6idine tablets, ranitidine ranitidine injection rani5idine tablets, ranitidine ranitidine injection ranitudine tablets, ranitidine ranitidine injection ranitjdine tablets, ranitidine ranitidine injection ranitkdine tablets, ranitidine ranitidine injection ranitodine tablets, ranitidine ranitidine injection ranit9dine tablets, ranitidine ranitidine injection ranit8dine tablets, ranitidine ranitidine injection ranitisine tablets, ranitidine ranitidine injection ranitixine tablets, ranitidine ranitidine injection raniticine tablets, ranitidine ranitidine injection ranitifine tablets, ranitidine ranitidine injection ranitirine tablets, ranitidine ranitidine injection ranitieine tablets, ranitidine ranitidine injection ranitidune tablets, ranitidine ranitidine injection ranitidjne tablets, ranitidine ranitidine injection ranitidkne tablets, ranitidine ranitidine injection ranitidone tablets, ranitidine ranitidine injection ranitid9ne tablets, ranitidine ranitidine injection ranitid8ne tablets, ranitidine ranitidine injection ranitidibe tablets, ranitidine ranitidine injection ranitidime tablets, ranitidine ranitidine injection ranitidije tablets, ranitidine ranitidine injection ranitidihe tablets, ranitidine ranitidine injection ranitidinw tablets, ranitidine ranitidine injection ranitidins tablets, ranitidine ranitidine injection ranitidind tablets, ranitidine ranitidine injection ranitidinr tablets, ranitidine ranitidine injection ranitidin4 tablets, ranitidine ranitidine injection ranitidin3 tablets, ranitidine ranitidine injection ranitidine rablets, ranitidine ranitidine injection ranitidine fablets, ranitidine ranitidine injection ranitidine gablets, ranitidine ranitidine injection ranitidine yablets, ranitidine ranitidine injection ranitidine 6ablets, ranitidine ranitidine injection ranitidine 5ablets, ranitidine ranitidine injection ranitidine tzblets, ranitidine ranitidine injection ranitidine tsblets, ranitidine ranitidine injection ranitidine twblets, ranitidine ranitidine injection ranitidine tqblets, ranitidine ranitidine injection ranitidine tavlets, ranitidine ranitidine injection ranitidine tanlets, ranitidine ranitidine injection ranitidine tahlets, ranitidine ranitidine injection ranitidine taglets, ranitidine ranitidine injection ranitidine tabkets, ranitidine ranitidine injection ranitidine tabpets, ranitidine ranitidine injection ranitidine taboets, ranitidine ranitidine injection ranitidine tablwts, ranitidine ranitidine injection ranitidine tablsts, ranitidine ranitidine injection ranitidine tabldts, ranitidine ranitidine injection ranitidine tablrts, ranitidine ranitidine injection ranitidine tabl4ts, ranitidine ranitidine injection ranitidine tabl3ts, ranitidine ranitidine injection ranitidine tablers, ranitidine ranitidine injection ranitidine tablefs, ranitidine ranitidine injection ranitidine tablegs, ranitidine ranitidine injection ranitidine tableys, ranitidine ranitidine injection ranitidine table6s, ranitidine ranitidine injection ranitidine table5s, ranitidine ranitidine injection ranitidine tableta, ranitidine ranitidine injection ranitidine tabletz, ranitidine ranitidine injection ranitidine tabletx, ranitidine ranitidine injection ranitidine tabletd, ranitidine ranitidine injection ranitidine tablete, ranitidine ranitidine injection ranitidine tabletw, anitidine ranitidine injection ranitidine tablets, rnitidine ranitidine injection ranitidine tablets, raitidine ranitidine injection ranitidine tablets, rantidine ranitidine injection ranitidine tablets, raniidine ranitidine injection ranitidine tablets, ranitdine ranitidine injection ranitidine tablets, ranitiine ranitidine injection ranitidine tablets, ranitidne ranitidine injection ranitidine tablets, ranitidie ranitidine injection ranitidine tablets, ranitidin ranitidine injection ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine anitidine injection ranitidine tablets, ranitidine rnitidine injection ranitidine tablets, ranitidine raitidine injection ranitidine tablets, ranitidine rantidine injection ranitidine tablets, ranitidine raniidine injection ranitidine tablets, ranitidine ranitdine injection ranitidine tablets, ranitidine ranitiine injection ranitidine tablets, ranitidine ranitidne injection ranitidine tablets, ranitidine ranitidie injection ranitidine tablets, ranitidine ranitidin injection ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine njection ranitidine tablets, ranitidine ranitidine ijection ranitidine tablets, ranitidine ranitidine inection ranitidine tablets, ranitidine ranitidine injction ranitidine tablets, ranitidine ranitidine injetion ranitidine tablets, ranitidine ranitidine injecion ranitidine tablets, ranitidine ranitidine injecton ranitidine tablets, ranitidine ranitidine injectin ranitidine tablets, ranitidine ranitidine injectio ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine injection anitidine tablets, ranitidine ranitidine injection rnitidine tablets, ranitidine ranitidine injection raitidine tablets, ranitidine ranitidine injection rantidine tablets, ranitidine ranitidine injection raniidine tablets, ranitidine ranitidine injection ranitdine tablets, ranitidine ranitidine injection ranitiine tablets, ranitidine ranitidine injection ranitidne tablets, ranitidine ranitidine injection ranitidie tablets, ranitidine ranitidine injection ranitidin tablets, ranitidine ranitidine injection ranitidinetablets, ranitidine ranitidine injection ranitidine ablets, ranitidine ranitidine injection ranitidine tblets, ranitidine ranitidine injection ranitidine talets, ranitidine ranitidine injection ranitidine tabets, ranitidine ranitidine injection ranitidine tablts, ranitidine ranitidine injection ranitidine tables, ranitidine ranitidine injection ranitidine tablet, arnitidine ranitidine injection ranitidine tablets, rnaitidine ranitidine injection ranitidine tablets, raintidine ranitidine injection ranitidine tablets, rantiidine ranitidine injection ranitidine tablets, raniitdine ranitidine injection ranitidine tablets, ranitdiine ranitidine injection ranitidine tablets, ranitiidne ranitidine injection ranitidine tablets, ranitidnie ranitidine injection ranitidine tablets, ranitidien ranitidine injection ranitidine tablets, ranitidin e ranitidine injection ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine r anitidine injection ranitidine tablets, ranitidine arnitidine injection ranitidine tablets, ranitidine rnaitidine injection ranitidine tablets, ranitidine raintidine injection ranitidine tablets, ranitidine rantiidine injection ranitidine tablets, ranitidine raniitdine injection ranitidine tablets, ranitidine ranitdiine injection ranitidine tablets, ranitidine ranitiidne injection ranitidine tablets, ranitidine ranitidnie injection ranitidine tablets, ranitidine ranitidien injection ranitidine tablets, ranitidine ranitidin e injection ranitidine tablets, ranitidine ranitidine i njection ranitidine tablets, ranitidine ranitidine nijection ranitidine tablets, ranitidine ranitidine ijnection ranitidine tablets, ranitidine ranitidine inejction ranitidine tablets, ranitidine ranitidine injcetion ranitidine tablets, ranitidine ranitidine injetcion ranitidine tablets, ranitidine ranitidine injeciton ranitidine tablets, ranitidine ranitidine injectoin ranitidine tablets, ranitidine ranitidine injectino ranitidine tablets, ranitidine ranitidine injectio n ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine injection r anitidine tablets, ranitidine ranitidine injection arnitidine tablets, ranitidine ranitidine injection rnaitidine tablets, ranitidine ranitidine injection raintidine tablets, ranitidine ranitidine injection rantiidine tablets, ranitidine ranitidine injection raniitdine tablets, ranitidine ranitidine injection ranitdiine tablets, ranitidine ranitidine injection ranitiidne tablets, ranitidine ranitidine injection ranitidnie tablets, ranitidine ranitidine injection ranitidien tablets, ranitidine ranitidine injection ranitidin etablets, ranitidine ranitidine injection ranitidinet ablets, ranitidine ranitidine injection ranitidine atblets, ranitidine ranitidine injection ranitidine tbalets, ranitidine ranitidine injection ranitidine talbets, ranitidine ranitidine injection ranitidine tabelts, ranitidine ranitidine injection ranitidine tabltes, ranitidine ranitidine injection ranitidine tablest, rranitidine ranitidine injection ranitidine tablets, raanitidine ranitidine injection ranitidine tablets, rannitidine ranitidine injection ranitidine tablets, raniitidine ranitidine injection ranitidine tablets, ranittidine ranitidine injection ranitidine tablets, ranitiidine ranitidine injection ranitidine tablets, ranitiddine ranitidine injection ranitidine tablets, ranitidiine ranitidine injection ranitidine tablets, ranitidinne ranitidine injection ranitidine tablets, ranitidinee ranitidine injection ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine rranitidine injection ranitidine tablets, ranitidine raanitidine injection ranitidine tablets, ranitidine rannitidine injection ranitidine tablets, ranitidine raniitidine injection ranitidine tablets, ranitidine ranittidine injection ranitidine tablets, ranitidine ranitiidine injection ranitidine tablets, ranitidine ranitiddine injection ranitidine tablets, ranitidine ranitidiine injection ranitidine tablets, ranitidine ranitidinne injection ranitidine tablets, ranitidine ranitidinee injection ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine iinjection ranitidine tablets, ranitidine ranitidine innjection ranitidine tablets, ranitidine ranitidine injjection ranitidine tablets, ranitidine ranitidine injeection ranitidine tablets, ranitidine ranitidine injecction ranitidine tablets, ranitidine ranitidine injecttion ranitidine tablets, ranitidine ranitidine injectiion ranitidine tablets, ranitidine ranitidine injectioon ranitidine tablets, ranitidine ranitidine injectionn ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine injection rranitidine tablets, ranitidine ranitidine injection raanitidine tablets, ranitidine ranitidine injection rannitidine tablets, ranitidine ranitidine injection raniitidine tablets, ranitidine ranitidine injection ranittidine tablets, ranitidine ranitidine injection ranitiidine tablets, ranitidine ranitidine injection ranitiddine tablets, ranitidine ranitidine injection ranitidiine tablets, ranitidine ranitidine injection ranitidinne tablets, ranitidine ranitidine injection ranitidinee tablets, ranitidine ranitidine injection ranitidine tablets, ranitidine ranitidine injection ranitidine ttablets, ranitidine ranitidine injection ranitidine taablets, ranitidine ranitidine injection ranitidine tabblets, ranitidine ranitidine injection ranitidine tabllets, ranitidine ranitidine injection ranitidine tableets, ranitidine ranitidine injection ranitidine tabletts, ranitidine ranitidine injection ranitidine tabletss, etc.

USA hospitals | Natural mosquito repellent | New 401k contribution limits | PMS | Blue waffles disease | Keratosis pilaris on face tretment


© Copyright by Drugspedia.net 2006-2007. All rights reserved